Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Quarterly Rx: 2025 U.S. Biopharma Recap

    The biopharma capital markets played through a volatile, but ultimately constructive, set this year.

    Read more

  • Inflation and Growth: The Balancing Act for 2026

    Investors and policymakers are preparing for a complex landscape in 2026. Learn why inflation remains stubbornly high, how central banks are responding, and what it means for investment strategies in the year ahead.

    Read more

  • U.S. LNG Exports Reshape Global Energy Markets

    Discover how skyrocketing LNG exports drive growth, boost energy security, and create new investment opportunities.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures